STAR Stock Overview Develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Strides Pharma Science Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Strides Pharma Science Historical stock prices Current Share Price ₹682.30 52 Week High ₹1,675.00 52 Week Low ₹603.00 Beta 0.78 1 Month Change -50.99% 3 Month Change -46.96% 1 Year Change 7.34% 3 Year Change 59.03% 5 Year Change 85.46% Change since IPO -23.82%
Recent News & Updates
Strides Pharma Science Limited completed the Spin-Off of OneSource Specialty Pharma Limited. Dec 12
New major risk - Share price stability Dec 06
Now 59% undervalued after recent price drop Dec 06
Strides Pharma Science Limited Announces Appointment of Dr. C Muthulingam as Executive Vice President - Research & Development Nov 21
Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors Nov 01
Second quarter 2025 earnings released: EPS: ₹10.14 (vs ₹14.54 loss in 2Q 2024) Oct 25 See more updates
Strides Pharma Science Limited completed the Spin-Off of OneSource Specialty Pharma Limited. Dec 12
New major risk - Share price stability Dec 06
Now 59% undervalued after recent price drop Dec 06
Strides Pharma Science Limited Announces Appointment of Dr. C Muthulingam as Executive Vice President - Research & Development Nov 21
Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors Nov 01
Second quarter 2025 earnings released: EPS: ₹10.14 (vs ₹14.54 loss in 2Q 2024) Oct 25
Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge Oct 21
Strides Pharma Science Limited to Report Q2, 2025 Results on Oct 24, 2024 Oct 18
Upcoming dividend of ₹2.50 per share Sep 02 Strides Pharma Science Limited, Annual General Meeting, Sep 25, 2024
After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar Aug 14
Strides Pharma Science Limited Announces Completion of Tenure of S Sridhar as Independent Director Jul 30
First quarter 2025 earnings released: EPS: ₹7.64 (vs ₹0.79 loss in 1Q 2024) Jul 30
Strides Pharma Science Limited to Report Q1, 2025 Results on Jul 29, 2024 Jul 22
Insufficient new directors Jun 24
New minor risk - Dividend sustainability May 25 Strides Pharma Science Limited Announces Chief Financial Officer Changes, Effective June 1, 2024
Price target increased by 20% to ₹994 May 24
Forecast breakeven date pushed back to 2025 May 23
Strides Pharma Science Limited to Report Q4, 2024 Results on May 22, 2024 May 16
Strides Pharma Science Limited Approves Appointment of Ameet P Hariani as Independent Director May 01
Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR) Apr 04
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet? Feb 29
Price target increased by 10% to ₹730 Jan 31
Third quarter 2024 earnings released: ₹0.49 loss per share (vs ₹8.86 loss in 3Q 2023) Jan 31
Strides Pharma Science Limited to Report Q3, 2024 Results on Jan 30, 2024 Jan 23
Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story Dec 23
Strides Pharma Global Pte. Limited Receives USFDA Approval for Generic Suprep®? Bowel Prep Kit Nov 23
Now 21% undervalued Nov 03
Strides Pharma Science Limited Announces Change in Management Oct 31
Second quarter 2024 earnings released: ₹14.54 loss per share (vs ₹0.47 profit in 2Q 2023) Oct 31
Strides Pharma Science Limited to Report Q2, 2024 Results on Oct 30, 2023 Oct 21
New major risk - Revenue and earnings growth Sep 26
We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt Sep 26
Strides Pharma Global Pte. Limited Receives Tentative United States Food & Drug Administration Approval for Dolutegravir Tablets Sep 16
Strides Pharma Science Limited Announces Resignation of Ankit Gupta as Vice President and Head of Corporate Development and Strategy Sep 02
Price target increased by 10% to ₹530 Aug 04
Upcoming dividend of ₹1.50 per share at 0.3% yield Jul 28
Strides Pharma Science Limited to Report Q1, 2024 Results on Aug 02, 2023 Jul 26
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet? Jun 08
Strides Pharma Science Limited Recommends Dividend for Financial Year Ended March 31, 2023 May 26
Full year 2023 earnings: EPS and revenues exceed analyst expectations May 26
Strides Pharma Science Limited to Report Q4, 2023 Results on May 25, 2023 May 19
Price target decreased by 7.2% to ₹462 May 17
Third quarter 2023 earnings released: ₹8.86 loss per share (vs ₹13.55 loss in 3Q 2022) Jan 25
Strides Pharma Science Limited to Report Q3, 2023 Results on Jan 24, 2023 Jan 18
Insufficient new directors Jan 01
Second quarter 2023 earnings released: EPS: ₹2.54 (vs ₹18.12 loss in 2Q 2022) Nov 16
Insufficient new directors Nov 16
Strides Pharma Science Limited Announces Resignation of Director Nov 15
Strides Pharma Science Limited to Report Q2, 2023 Results on Nov 14, 2022 Nov 09
Strides Pharma Science Limited, Annual General Meeting, Sep 09, 2022 Aug 19
Strides Pharma Science Limited, Annual General Meeting, Sep 09, 2022 Aug 18
Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates Aug 02
First quarter 2023 earnings released: ₹15.13 loss per share (vs ₹22.88 loss in 1Q 2022) Jul 30
Strides Pharma Science Limited to Report Q1, 2023 Results on Jul 29, 2022 Jul 23
Is Strides Pharma Science (NSE:STAR) A Risky Investment? Jun 25
Stelis Biopharma Limited and Strides Pharma Science Limited Receive the European Union Goods Manufacturing Practices (EU-GMP) Compliance Certificate Jun 17
Now 20% undervalued after recent price drop Jun 16
Strides Receives USFDA Approval for Ibuprofen Oral Suspension May 31
Full year 2022 earnings: EPS misses analyst expectations May 26
Strides Pharma Science Limited to Report Q4, 2022 Results on May 24, 2022 May 17
Price target decreased to ₹463 Apr 27
Insufficient new directors Apr 27
Insufficient new directors Apr 01 Strides Pharma Science Limited Announces Executive Changes
Founder & Non-Executive Chairman recently bought ₹50m worth of stock Mar 05
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Feb 13 Strides Pharma Science Limited announced that it expects to receive INR 485 million in funding from Karuna Business Solutions LLP Feb 11
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet? Dec 21
Price target decreased to ₹735 Nov 12
Second quarter 2022 earnings released: ₹18.12 loss per share (vs ₹7.38 profit in 2Q 2021) Nov 11
Insider recently sold ₹1.5m worth of stock Sep 23
Insider recently sold ₹14m worth of stock Aug 14
First quarter 2022 earnings released: ₹22.88 loss per share (vs ₹11.56 profit in 1Q 2021) Aug 09
Less than half of directors are independent Aug 07
Upcoming dividend of ₹2.50 per share Jul 29
Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50 Jul 28
Insider recently sold ₹2.8m worth of stock Jul 03
Chief Human Resource Officer recently sold ₹4.1m worth of stock Jun 18 TLC and Strides Pharma Science Limited Partner to Launch Liposomal Amphotericin B in India
Full year 2021 earnings released: EPS ₹28.40 (vs ₹5.49 in FY 2020) May 28
Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR) Apr 13
Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio? Mar 04
These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively Feb 15
Analysts lower EPS estimates to ₹25.17 Feb 11
Price target raised to ₹886 Feb 06
Third quarter 2021 earnings released: EPS ₹4.22 (vs ₹10.48 in 3Q 2020) Feb 06
Revenue and earnings miss expectations Feb 06
Strides Pharma Science Limited to Report Q3, 2021 Results on Feb 04, 2021 Jan 29 Shareholder Returns STAR IN Pharmaceuticals IN Market 7D -4.6% 1.8% -2.1% 1Y 7.3% 43.7% 22.5%
See full shareholder returns
Return vs Market: STAR underperformed the Indian Market which returned 22.5% over the past year.
Price Volatility Is STAR's price volatile compared to industry and market? STAR volatility STAR Average Weekly Movement 16.8% Pharmaceuticals Industry Average Movement 5.9% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.1% 10% least volatile stocks in IN Market 4.1%
Stable Share Price: STAR's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: STAR's weekly volatility has increased from 10% to 17% over the past year.
About the Company Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams.
Show more Strides Pharma Science Limited Fundamentals Summary How do Strides Pharma Science's earnings and revenue compare to its market cap? STAR fundamental statistics Market cap ₹62.74b Earnings (TTM ) ₹1.77b Revenue (TTM ) ₹44.10b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) STAR income statement (TTM ) Revenue ₹44.10b Cost of Revenue ₹19.25b Gross Profit ₹24.85b Other Expenses ₹23.08b Earnings ₹1.77b
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 19.25 Gross Margin 56.35% Net Profit Margin 4.01% Debt/Equity Ratio 100.0%
How did STAR perform over the long term?
See historical performance and comparison Dividends
0.4% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 22:19 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Strides Pharma Science Limited is covered by 20 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Aditya Khemka Ambit Capital Harith Ahamed Avendus Spark Prakash Agarwal Axis Capital Limited
Show 17 more analysts 
